The Los Angeles Times on Sunday examined how the business "strategy that has made the pharmaceutical industry one of the wealthiest and most powerful on Earth" might have begun to "betray it." 

Pharmaceutical companies for 25 years have "imitated the basic business model of Hollywood" and have "focused on creating blockbusters," which they "hope will appeal to masses" and "promote like mad," according to the Times. Pharmaceutical companies must spend as much as $1 billion to promote new medications in their first two years on the market to make the products into a "mega-brand" with at least $1 billion in annual sales.

"Only now is it becoming clear that this business model couldn’t work forever," as the strategy "had a flaw that executives have long ignored" — the approach "required extraordinary amounts of promotion at the expense of scientific creativity," the Times reports. During the next several years, pharmaceutical companies will lose patent protection on a number of popular and profitable medications — such as the osteoporosis treatment Fosamax, manufactured by Merck, the antipsychotic Risperdal, manufactured by Johnson & Johnson, and the cholesterol medication Lipitor, manufactured by Pfizer — and the "industry’s scientists have hit a dry spell" and are "not discovering enough new drugs to replace the aging standbys," the Times reports.

"It would be wrong to believe that this is the end of the industry’s wealth and power," but, as some pharmaceutical companies "struggle, patients will bear the brunt," with the prices of medications likely to "rise even faster," according to the Times (Petersen, Los Angeles Times, 1/27).



We're here to help!

We live by our creed of "helping those who need it most" and have helped thousands of clients get the justice they desperately needed and deserved. If you feel you have a case or just have questions please contact us for a free consultation. There is no risk and no fees unless we win for you.

Fields marked    may be required for submission.
  1. I'm an attorney

Number of Risperdal lawsuits continues climbing

The number of Risperdal cases has increased for the second consecutive year in the Philadelphia mass...
Risperdal Side Effects

Risperdal plaintiff granted retrial against J&J,...

Like thousands of other plaintiffs, W.C. alleges the defendants didn’t adequately warn about the risk...
Risperdal Side Effects

New York man awarded $1M in Risperdal gynecomastia...

Risperdal has been linked to a condition called gynecomastia, in which males grow female-like breasts....
Risperdal Side Effects

No new trial for Janssen Pharmaceutical in $2.5...

The company was seeking a new trial as part of an effort to overturn a $2.5 million jury verdict that...
Risperdal Side Effects

Risperdal legal troubles continue to mount

The suit was filed by a number of child advocacy organizations on behalf of children in the Missouri...
Risperdal Side Effects

Johnson & Johnson, Janssen Pharmaceuticals legal...

Plaintiffs contend Janssen concealed the risk of Risperdal’s most devastating side effect,...

Thanks and deep appreciation for all your work

Thanks and deep appreciation for all your work and expertise. We were able to afford many things with our settlement. Many, many thanks again and again. God bless you always.

—Thelma